[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-alcoholic-hepatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-alcoholic-hepatitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100370681","study-of-genetic-determinants-in-alcoholic-hepatitis-and-establishment-of-a-multicenter-prospective-cohort-of-patients-with-alcoholic-liver-disease-100370681",false,"NCT04106518","Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease","COMADHAA","Inclusion Criteria:\n\nFor SAH group:\n\n* Alcohol consumption :\n\n  * On average\\> 40 g \u002F day for women and 50 g \u002F day for men\n  * Duration:\\> 5 years\n* Recent jaundice episode (less than 3 months)\n* Bilirubin\\> 50 mg \u002F l (85μmol \u002F l)\n\nFor NSAH group:\n\n\\- Alcohol consumption :\n\n* On average\\> 40 g \u002F day for women and 50 g \u002F day for men\n* Duration:\\> 5 years\n\nFor cirrhosis (control) group:\n\n* Alcohol consumption :\n\n  * On average\\> 40 g \u002F day for women and 50 g \u002F day for men\n  * Duration:\\> 5 years\n* Unambiguous presence of cirrhosis criteria, including:\n\n  * clinical signs (ascites, stellar angiomas ...) and \u002F or\n  * radiological signs (scanner or MRI: signs of hepatic dysmorphism and \u002F or portal hypertension) and \u002F or\n  * biological signs (increased INR, thrombocytopenia) and \u002F or\n  * endoscopic signs (oesophageal \u002F gastric varices)\n\nExclusion Criteria:\n\nFor NAH and NSAH groups:\n\n* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)\n* Presence of hepatocellular carcinoma\n* HIV infection\n\nFor cirrhosis (control) group:\n\n* History established \u002F suggestive of HAA (Clinical, biological and \u002F or histological criteria) in particular absence of jaundice episode\n* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)\n* Presence of hepatocellular carcinoma\n* HIV infection","ALL","18 Years",{"count":19,"type":20},447,"ESTIMATED","5 Years","OBSERVATIONAL","Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy. The prevalence of alcoholic hepatitis, severe or not severe, is poorly known and prospective data are needed. The present observational study aims to define the prevalence of alcoholic hepatitis among patients admitted for jaundice and determine their outcome according to the severity. Survival and markers of liver dysfunction will be assessed. A biobank including genetic samples will be created to identify the disease profile in terms of inflammation and regeneration. The performance of non-invasive criteria for diagnosis will also be studied.",[25,26,27],"Alcoholic Liver Disease","Severe Alcoholic Hepatitis","Alcoholic Cirrhosis",[29,30,31,32,33,34],"Cohort","alcoholic hepatitis","alcoholic cirrhosis","pathophysiology","bio bank","pan-genomic study","RECRUITING","2026-05-18",{"date":38,"type":39},"2026-05-19","ACTUAL",{"date":41,"type":39},"2019-10-23",{"date":43,"type":20},"2027-04",{"name":45,"class":46},"University Hospital, Lille","OTHER",9,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100606529","livertrem-1-hepatic-trem-1-expression-and-prognosis-in-severe-alcoholic-hepatitis-100606529","NCT07176741","LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis","Measurement of Hepatocyte TREM-1 Expression Level to Evaluate Its Intrinsic Performance and Prognostic Value in Severe Symptomatic Alcohol-related Hepatitis","Liver TREM-1","Inclusion Criteria:\n\nCases:\n\n* Individuals who received full information about the study and did not object to the use of their data within this research.\n* Patients managed in one of the intensive care or hepatogastroenterology departments at CHRU de Nancy for severe alcohol-related hepatitis between January 1, 2013, and December 31, 2023.\n* Archived liver biopsy slides available at CHRU de Nancy.\n* Adult patients at the time of diagnosis.\n\nControls:\n\n* Individuals who received full information about the study and did not object to the use of their data within this research.\n* Patients treated and operated on at CHRU de Nancy for hepatocellular carcinoma, colorectal cancer liver metastasis, or cholangiocarcinoma between January 1, 2013, and December 31, 2023.\n* Archived liver biopsy slides available at CHRU de Nancy.\n* Adult patients at the time of diagnosis.\n\nExclusion Criteria:\n\n• None",{"count":57,"type":20},300,"Background \\& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of \\~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and histological indicators. Corticosteroids-the only validated treatment-are only effective in 50% of cases and can worsen outcomes in non-responders by promoting infections. Liver transplantation remains a limited option due to organ scarcity and patient eligibility.\n\nTREM-1, a pro-inflammatory receptor, has shown promise in inflammatory liver diseases. Its expression in hepatocytes may serve as a biomarker to better classify patients, guide treatment, and improve outcomes.\n\nObjectives\n\nPrimary Objective:\n\nCompare TREM-1 expression (via immunohistochemistry) between SAH patients and controls with other liver diseases (e.g., HCC, metastatic colon cancer, cholangiocarcinoma).\n\nSecondary Objectives:\n\nDetermine optimal antibody dilution for TREM-1 staining.\n\nAssess diagnostic performance (sensitivity, specificity, PPV, NPV).\n\nIdentify homogeneous SAH subgroups using clinical, histological, and biological data.\n\nEvaluate prognostic value of TREM-1 expression for:\n\n2-month mortality\n\nCorticosteroid response (bilirubin regression at Day 7)\n\nLille score \\\u003C0.45 at Day 7\n\nCompare TREM-1's predictive power to standard scores (MELD, Maddrey, Lille, etc.).\n\nMethodology\n\nPopulation:\n\nCases: Adults treated at CHRU de Nancy (2013-2023) for SAH, with archived liver biopsies.\n\nControls: Adults with liver malignancies and archived biopsies.\n\nSample Size:\n\nPhase I: 12 cases, 6 controls\n\nPhase II: 150 cases, 150 controls\n\nData Sources: Medical records, archived pathology slides\n\nStatistical Tools: Logistic regression, survival analysis, ROC curves, clustering, SAS\u002FR software\n\nExpected Outcomes \\& Impact Improved prognostic stratification and therapeutic guidance for SAH patients\n\nBetter targeting of corticosteroid therapy to reduce unnecessary risk\n\nEarly referral for liver transplantation when appropriate\n\nValidation of TREM-1 as a diagnostic\u002Fprognostic biomarker\n\nFoundation for future TREM-1-targeted clinical trials\n\nPotential paradigm shift linking liver histology with real-time clinical decision-making\n\nEnhanced resource allocation and patient management",[26],[61,62,63,64,30,65,66,67],"TREM-1","sAH","biomarker","prognosis","alcohol use disorder","AUD","cirrhosis","NOT_YET_RECRUITING","2025-09-09",{"date":71,"type":39},"2025-09-16",{"date":73,"type":20},"2025-10-01",{"date":75,"type":20},"2026-12",{"name":77,"class":46},"Central Hospital, Nancy, France"]